MedTrace Logo

PET Scan in Treating Patients With Metastatic Prostate Cancer

NCT00002981 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 173

Last updated 2024-06-03

Study results available
· View outcomes & findings →

Summary

RATIONALE: New imaging procedures, such as PET scan, may improve the ability to detect new or recurrent prostate cancer.

Conditions

Interventions

PROCEDURE

positron emission tomography

RADIATION

fludeoxyglucose F 18

RADIATION

methionine C 11

Sponsors & Collaborators

Principal Investigators

  • Steven M. Larson, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
0 Years
Max Age
120 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-01-31
Primary Completion
2023-06-12
Completion
2023-06-12

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002981 on ClinicalTrials.gov